Document is current
Any future updates will be listed below
-
Authors
Pace, Alex
Roda, Weston
Poon, Corrina
McMillan, Hugh J.
Oskoui, Maryam
MacKenzie, Alex
Chakraborty, Pranesh
Round, Jeff
-
Funding
Funding for this research was provided by:
Muscular Dystrophy Canada (Muscular Dystrophy Canada)
- License Information
-
More Information
Article History
Received: 10 October 2024
Accepted: 16 July 2025
First Online: 13 August 2025
Declarations
:
: Not applicable.
: Not applicable.
: HM has been a consultant and received honararia from Novartis Gene Therapies Inc, Hoffman La-Roche Ltd and Pfizer. He has participated in clinical trials with Roche, PTC Therapeutics, Biogen, DYNE, PepGen, ReveraGen, Catabasis, Novartis, and Sarepta. MO has received research support from Roche Genetech, Novartis, Santhera, Muscular Dystrophy Canada, Canadian Institutes of Health Research. PC has received research support from Biogen, Biomarin, Takeda, Cambrooke, Vitaflo, Nutricia, NFDC, CIHR and CF foundation. He has also served on advisory boards for Sanofi, Ultragenyx, Waters and Horizon. JR and his employer (The Institute of Health Economics) received no additional funding directly related to this work. AP has no disclosures to report. CP has no disclosures to report. WR has no disclosures to report. AM has no disclosures to report.
